급성 세균성 피부 및 피부 구조 감염증(ABSSSI) 치료 시장 규모, 점유율, 동향 및 성장 분석 보고서(2026-2034년)

The Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Treatment Market size is expected to reach USD 2.87 Billion in 2034 from USD 1.80 Billion (2025) growing at a CAGR of 5.32% during 2026-2034.

The global acute bacterial skin and skin structure infections (ABSSSI) treatment market is expanding due to the increasing incidence of bacterial infections affecting the skin and underlying tissues. These infections can range from mild conditions such as cellulitis to severe infections that require immediate medical treatment. Effective antibiotics and advanced treatment options are essential to manage these infections and prevent complications.

One of the major drivers of the ABSSSI treatment market is the rising prevalence of antibiotic-resistant bacteria. Healthcare providers are focusing on developing and adopting new antimicrobial therapies that can effectively treat resistant infections. Additionally, the increasing number of hospital admissions and surgical procedures is contributing to the demand for advanced infection treatment solutions.

The future outlook for the ABSSSI treatment market remains promising as pharmaceutical companies continue to invest in research and development of new antibiotics and targeted therapies. Advances in diagnostic technologies are also helping healthcare professionals detect infections earlier and provide timely treatment. These innovations are expected to improve patient outcomes and support market growth.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Infection Type

• Community-Acquired ABSSSI
• Hospital-Acquired ABSSSI

By Drug Class

• Glycopeptides/Lipoglycopeptides
• Oxazolidinones
• Beta-lactams
• Lipopeptide
• Tetracyclines
• Other Drug Classes

By Route of Administration

• Parenteral
• Oral
• Topical

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

COMPANIES PROFILED

• AbbVie, Basilea Pharmaceutica, Cipher Pharmaceuticals, Endo Pharmaceuticals, Glenmark Pharmaceuticals, Melinta Therapeutics, Menarini Group, Merck, Nabriva Therapeutics, Paratek Pharmaceuticals, Pfizer, Sandoz
• We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL ACUTE BACTERIAL SKIN AND SKIN STRUCTURE INFECTIONS (ABSSSI) TREATMENT MARKET: BY INFECTION TYPE 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Infection Type
• 4.2. Community-Acquired ABSSSI Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Hospital-Acquired ABSSSI Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL ACUTE BACTERIAL SKIN AND SKIN STRUCTURE INFECTIONS (ABSSSI) TREATMENT MARKET: BY DRUG CLASS 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Drug Class
• 5.2. Glycopeptides/Lipoglycopeptides Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Oxazolidinones Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Beta-lactams Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.5. Lipopeptide Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.6. Tetracyclines Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.7. Other Drug Classes Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL ACUTE BACTERIAL SKIN AND SKIN STRUCTURE INFECTIONS (ABSSSI) TREATMENT MARKET: BY ROUTE OF ADMINISTRATION 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast Route Of Administration
• 6.2. Parenteral Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Oral Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.4. Topical Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL ACUTE BACTERIAL SKIN AND SKIN STRUCTURE INFECTIONS (ABSSSI) TREATMENT MARKET: BY DISTRIBUTION CHANNEL 2022-2034 (USD MN)

• 7.1. Market Analysis, Insights and Forecast Distribution Channel
• 7.2. Hospital Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.3. Retail Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.4. Online Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 8. GLOBAL ACUTE BACTERIAL SKIN AND SKIN STRUCTURE INFECTIONS (ABSSSI) TREATMENT MARKET: BY REGION 2022-2034 (USD MN)

• 8.1. Regional Outlook
• 8.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.2.1 By Infection Type
  • 8.2.2 By Drug Class
  • 8.2.3 By Route Of Administration
  • 8.2.4 By Distribution Channel
  • 8.2.5 United States
  • 8.2.6 Canada
  • 8.2.7 Mexico
• 8.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.3.1 By Infection Type
  • 8.3.2 By Drug Class
  • 8.3.3 By Route Of Administration
  • 8.3.4 By Distribution Channel
  • 8.3.5 United Kingdom
  • 8.3.6 France
  • 8.3.7 Germany
  • 8.3.8 Italy
  • 8.3.9 Russia
  • 8.3.10 Rest Of Europe
• 8.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.4.1 By Infection Type
  • 8.4.2 By Drug Class
  • 8.4.3 By Route Of Administration
  • 8.4.4 By Distribution Channel
  • 8.4.5 India
  • 8.4.6 Japan
  • 8.4.7 South Korea
  • 8.4.8 Australia
  • 8.4.9 South East Asia
  • 8.4.10 Rest Of Asia Pacific
• 8.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.5.1 By Infection Type
  • 8.5.2 By Drug Class
  • 8.5.3 By Route Of Administration
  • 8.5.4 By Distribution Channel
  • 8.5.5 Brazil
  • 8.5.6 Argentina
  • 8.5.7 Peru
  • 8.5.8 Chile
  • 8.5.9 Rest of Latin America
• 8.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.6.1 By Infection Type
  • 8.6.2 By Drug Class
  • 8.6.3 By Route Of Administration
  • 8.6.4 By Distribution Channel
  • 8.6.5 Saudi Arabia
  • 8.6.6 UAE
  • 8.6.7 Israel
  • 8.6.8 South Africa
  • 8.6.9 Rest of the Middle East And Africa

Chapter 9. COMPETITIVE LANDSCAPE

• 9.1. Recent Developments
• 9.2. Company Categorization
• 9.3. Supply Chain & Channel Partners (based on availability)
• 9.4. Market Share & Positioning Analysis (based on availability)
• 9.5. Vendor Landscape (based on availability)
• 9.6. Strategy Mapping

Chapter 10. COMPANY PROFILES OF GLOBAL ACUTE BACTERIAL SKIN AND SKIN STRUCTURE INFECTIONS (ABSSSI) TREATMENT INDUSTRY

• 10.1. Top Companies Market Share Analysis
• 10.2. Company Profiles
  • 10.2.1 AbbVie
  • 10.2.2 Basilea Pharmaceutica
  • 10.2.3 Cipher Pharmaceuticals
  • 10.2.4 Endo Pharmaceuticals
  • 10.2.5 Glenmark Pharmaceuticals
  • 10.2.6 Melinta Therapeutics
  • 10.2.7 Menarini Group
  • 10.2.8 Merck
  • 10.2.9 Nabriva Therapeutics
  • 10.2.10 Paratek Pharmaceuticals
  • 10.2.11 Pfizer
  • 10.2.12 Sandoz